AXSM Q3 2021 Earnings — Axsome Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

AXSMAxsome Therapeutics, Inc.

$8B

Q3 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$33M

Net Income

-$35M

EPS (Diluted)

$-0.93

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$27M

Free Cash Flow

-$27M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$117M

Total Liabilities

$74M

Stockholders' Equity

$43M

Cash & Equivalents

$115M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$33M	-$21M	-58.1%
Net Income	-$35M	-$23M	-52.2%